Latest news : Gamida Cell Ltd.

27/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
23/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations: Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	58	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets Other stock markets 19:54:51 24/05/2024 +03			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.29M 2.11M 1.95M 3.71M 250M 3.77M 25.29M 9.92M 123M 9.83M 9.62M 425M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 34.12M 31.47M 29.12M 55.26M 3.72B 56.19M 377M 148M 1.83B 146M 143M 6.33B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.66
5 years	0.01	6.31
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/01/24	Kenneth Moch	Free	Director	200,000	0.1508%
31/01/24	Stephen Wills	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.96%	2.62M
ARGENX SE	-0.38%	-3.44%	+71.35%	+126.62%	56.71B
WUXI APPTEC CO., LTD.	+4.91%	-3.30%	+71.97%	+92.14%	51.3B
INSMED INCORPORATED	+1.87%	+6.33%	+23.00%	+481.67%	25.26B
BIONTECH SE	-0.67%	-4.66%	-16.80%	-13.43%	23.65B
WUXI BIOLOGICS (CAYMAN) INC.	+3.93%	+7.11%	+44.20%	-1.96%	18.69B
GENMAB A/S	+2.01%	+2.99%	+40.72%	-24.46%	17.71B
PHARMAESSENTIA CORPORATION	-6.84%	+4.81%	+201.88%	+348.11%	17.7B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.92%	+8.90%	+38.48%	-	14.26B
EXELIXIS, INC.	+1.75%	+2.02%	+29.29%	+198.79%	14.1B
Average	+0.81%	+3.47%	+50.41%	+123.17%	23.94B
Weighted average by Cap.	+1.10%	+2.16%	+58.50%	+143.26%

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

	2022	2023
Net sales	-	1.78 1.56 1.44 1.33 2.53 170.29 2.57 17.24 6.76 83.62 6.7 6.55 289.66
Net income	-79.38M -69.44M -64.03M -59.25M -112M -7.58B -114M -767M -301M -3.72B -298M -292M -12.89B	-63M -55.11M -50.82M -47.02M -89.25M -6.01B -90.74M -609M -239M -2.95B -236M -231M -10.23B
Net Debt	39.31M 34.39M 31.71M 29.34M 55.69M 3.75B 56.62M 380M 149M 1.84B 148M 144M 6.38B	36.39M 31.83M 29.36M 27.16M 51.55M 3.47B 52.41M 352M 138M 1.71B 137M 134M 5.91B